Citations

Showing 10 of 108104 citations.

Mitochondrial pyruvate carrier-mediated metabolism is dispensable for the classical activation of macrophages
Ran, Linyu, Zhang, Song , Zhao, Pei , Sun, Jiaxing , Gan, Haiyun , Li, Qiang , Herrmann, Joerg , Zhang, Song , Ran, Linyu, Zhou, Jiaqi, Jeon, Ryoung‐Hoon , Wang, Feilong

Mayo Clinic

No container title available | March 10, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1413776/v1 Get It

Abstract Glycolysis is essential for the classical activation of macrophages (M1), but how glycolytic pathway metabolites engage in this process remains to be elucidated. Glycolysis culminates in the production of pyruvate, which can be transported into the mitochondria by the mitochondrial pyruvate carrier (MPC) followed by conversion to citrate and utilization in the TCA cycle. Alternatively, pyruvate can be metabolized to lactate under aerobic conditions, which had been considered to be the dominant route in the setting of classical macrophage activation. However, based on studies that used UK5099 as a MPC inhibitor and showed reduction in key inflammatory cytokines, the mitochondrial route has been considered to be of significance for M1 activation as well. Herein, using a genetic depletion model, we found that MPC is dispensable for metabolic reprogramming and the activation of M1. In addition, MPC depletion in myeloid cells has no impact on inflammatory responses and macrophage polarization toward M1 phenotype in the endotoxemia mice model. While UK5099 reaches maximal MPC inhibitory capacity at approximately 2–5µM, higher concentrations are required to inhibit inflammatory cytokine production in M1 and this is independent of MPC expression. Taken together, this study found MPC-mediated metabolism is dispensable for the classical activation of macrophages, and UK5099 inhibits inflammatory responses in M1 macrophages due to effects other than MPC inhibition.
Cost-effectiveness Analysis of Early Sling Loosening Versus Delayed Sling Lysis in the Management of Voiding Dysfunction After Midurethral Sling Placement
Maldonado, Darlene Vargas, Wymer, Kevin M., Gebhart, John B., Madsen, Annetta M., Occhino, John A., Trabuco, Emanuel C., Linder, Brian J., Linder, Brian J. , Linder, Brian J , Maldonado, Darlene Vargas, Wymer, Kevin M., Gebhart, John B., Madsen, Annetta M., Occhino, John A., Trabuco, Emanuel C.

Mayo Clinic

Female Pelvic Medicine & Reconstructive Surgery | March 10, 2022 | Volume: 28 | Issue: 3 | Pages: e103-e107

10.1097/spv.0000000000001165 | PMID 35272342 Get It

Objective The aim of this study was to perform a cost-effectiveness analysis comparing the management for ongoing voiding dysfunction after midurethral sling placement, including early sling loosening and delayed sling lysis. Methods A Markov model was created to compare the cost-effectiveness of early sling loosening (2 weeks) versus delayed sling lysis (6 weeks) for the management of persisting voiding dysfunction/retention after midurethral sling placement. A literature review provided rates of resolution of voiding dysfunction with conservative management, complications, recurrent stress urinary incontinence, or ongoing retention, as well as quality-adjusted life years (QALYs). Costs were based on 2020 Medicare reimbursement rates. Incremental cost-effectiveness ratios were compared using a willingness-to-pay threshold of $100,000/QALY. One-way and probabilistic sensitivity analyses were performed. Results At 1 year, early sling loosening resulted in increased costs ($3,575 vs $1,836) and higher QALYs (0.948 vs 0.925) compared with delayed sling lysis. This translated to early sling loosening being the most cost-effective strategy, with an incremental cost-effectiveness ratio of $74,382/QALY. The model was sensitive to multiple variables on our 1-way sensitivity analysis. For example, delayed sling lysis became cost-effective if the rate of voiding dysfunction resolution with conservative management was greater than or equal to 57% or recurrent stress urinary incontinence after early loosening was greater than or equal to 9.6%. At a willingness-to-pay threshold of 100,000/QALY, early sling loosening was cost-effective in 82% of microsimulations in probabilistic sensitivity analysis. Conclusions Early sling loosening represents a more cost-effective management method in resolving ongoing voiding dysfunction after sling placement. These findings may favor early clinical management in patients with voiding dysfunction after midurethral sling placement.
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Teachey, David T. , Devidas, Meenakshi , Wood, Brent L. , Chen, Zhiguo , Hayashi, Robert J. , Hermiston, Michelle L. , Annett, Robert D. , Archer, Jan-Michael , Asselin, Barbara L. , August, Keith J. , Fisher, Brian T. , Galardy, Paul J. , Harker‐Murray, Paul , Jaju, Alok , Lam, Allison, Miles, Rodney R., Okada, Maki , Patel, Samir , Schechter, Tal , Singh, Neelam, Steele, Amii C., Sulis, Maria Luisa , Vargas, Sarah , Wood, Charlotte, Bollard, Catherine M. , Loh, Mignon L. , Raetz, Elizabeth A. , Archer, J Hunter , Dunsmore, Kimberly P , Fisher, Brian T , Horton, Terzah M. , Jaju, Alok I , Messinger, Yoav H , Schafer, Eric S , Winter, Stuart S , Bollard, Catherine M , Loh, Mignon L , Hunger, Stephen P , Wood, Brent L , August, Keith , Devidas, Meenakshi , Cho, Steve Y. , Freedman, Jason Lawrence , Messinger, Yoav H. , Schafer, Eric S. , Winter, Stuart S. , Zweidler-McKay, Patrick A , Hunger, Stephen P.

Mayo Clinic

Journal of Clinical Oncology | March 10, 2022 | Volume: 40 | Issue: 19 | Pages: 2106-2118

10.1200/jco.21.02678 | PMID 35271306 Get It

PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which also attempted to reduce the use of prophylactic cranial radiation (CRT) in newly diagnosed T-ALL. PATIENTS AND METHODS Children and young adults with T-ALL/T-LL were randomly assigned to a modified augmented Berlin-Frankfurt-Münster chemotherapy regimen with/without bortezomib during induction and delayed intensification. Multiple modifications were made to the augmented Berlin-Frankfurt-Münster backbone used in the predecessor trial, AALL0434, including using dexamethasone instead of prednisone and adding two extra doses of pegaspargase in an attempt to eliminate CRT in most patients. RESULTS AALL1231 accrued 824 eligible and evaluable patients from 2014 to 2017. The 4-year event-free survival (EFS) and overall survival (OS) for arm A (no bortezomib) versus arm B (bortezomib) were 80.1% ± 2.3% versus 83.8% ± 2.1% (EFS, P = .131) and 85.7% ± 2.0% versus 88.3% ± 1.8% (OS, P = .085). Patients with T-LL had improved EFS and OS with bortezomib: 4-year EFS (76.5% ± 5.1% v 86.4% ± 4.0%; P = .041); and 4-year OS (78.3% ± 4.9% v 89.5% ± 3.6%; P = .009). No excess toxicity was seen with bortezomib. In AALL0434, 90.8% of patients with T-ALL received CRT. In AALL1231, 9.5% of patients were scheduled to receive CRT. Evaluation of comparable AALL0434 patients who received CRT and AALL1231 patients who did not receive CRT demonstrated no statistical differences in EFS ( P = .412) and OS ( P = .600). CONCLUSION Patients with T-LL had significantly improved EFS and OS with bortezomib on the AALL1231 backbone. Systemic therapy intensification allowed elimination of CRT in more than 90% of patients with T-ALL without excess relapse.
Hypothyroid Patients Describe What Brain Fog Feels Like
Shah, Aashka , Maraka, Spyridoula

Mayo Clinic

Clinical Thyroidology | March 10, 2022 | Volume: 34 | Issue: 3 | Pages: 106-108

10.1089/ct.2022;34.106-108 Get It

The Impact of Wearable Breast Pumps on Physicians' Breastfeeding Experience and Success
Colbenson, Gretchen A. , Hoff, Olivia C., Olson, Emily M. , Ducharme‐Smith, Allison

Mayo Clinic

Breastfeeding Medicine | March 10, 2022 | Volume: 17 | Issue: 6 | Pages: 537-543

10.1089/bfm.2021.0266 | PMID 35271350 Get It

Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas
Wickland, Daniel P. , Sherman, Mark E. , Mansfield, Aaron S. , Asmann, Yan W. , Radisky, Derek C. , Mansfield, Aaron S , Asmann, Yan W

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 10, 2022 | Volume: 114 | Issue: 8 | Pages: 1192-1199

10.1093/jnci/djac054 | PMID 35299252 Get It

Abstract Background In the United States, cancer disproportionately impacts Black and African American individuals. Identifying genetic factors underlying cancer disparities has been an important research focus and requires data that are equitable in both quantity and quality across racial groups. It is widely recognized that DNA databases quantitatively underrepresent minorities. However, the differences in data quality between racial groups have not been well studied. Methods We compared the qualities of germline and tumor exomes between ancestrally African and European patients in The Cancer Genome Atlas of 7 cancers with at least 50 self-reported Black patients in the context of sequencing depth, tumor purity, and qualities of germline variants and somatic mutations. Results Germline and tumor exomes from ancestrally African patients were sequenced at statistically significantly lower depth in 6 out of the 7 cancers. For 3 cancers, most ancestrally European exomes were sequenced in early sample batches at higher depth, whereas ancestrally African exomes were concentrated in later batches and sequenced at much lower depth. For the other 3 cancers, the reasons of lower sequencing coverage of ancestrally African exomes remain unknown. Furthermore, even when the sequencing depths were comparable, African exomes had disproportionally higher percentages of positions with insufficient coverage, likely because of the known European bias in the human reference genome that impacted exome capture kit design. Conclusions Overall and positional lower sequencing depths of ancestrally African exomes in The Cancer Genome Atlas led to underdetection and lower quality of variants, highlighting the need to consider epidemiological factors for future genomics studies.
A 76‐year‐old male with multiple enhancing brain lesions
Eschbacher, Kathryn L. , Orozco‐Do, Sylvia L., Jawaid, Tabinda , Nguyen, Aivi T. , Nguyen, Aivi T , Johnson, Derek R. , Orozco-Do, Sylvia, Schuetz, Audrey N.

Mayo Clinic

Brain Pathology | March 10, 2022 | Volume: 32 | Issue: 3 | Pages: No page available

10.1111/bpa.13063 | PMID 35267225 Get It

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
Goyal, Gaurav , Tazi, Abdellatif , Picarsic, Jennifer , Vassallo, Robert , Cox, Christian W. , Laar, Jan van , Hermiston, Michelle L. , Haroche, Julien , Girschikofsky, Michael , Picarsic, Jennifer L , Cox, Christian W , van Laar, Jan A M , Cao, Xin-Xin , Makras, Polyzois , Kaltsas, Gregory , McClain, Kenneth L , Diamond, Eli L , Goyal, Guarav , Vassallo, Robert , Go, Ronald S. , Rech, Karen L. , Young, Jason R. , Makras, Polyzois , Kaltsas, Gregory , Collin, Matthew , McClain, Kenneth L. , Diamond, Eli L.

Mayo Clinic

Blood | March 10, 2022 | Volume: 139 | Issue: 17 | Pages: 2601-2621

10.1182/blood.2021014343 | PMID 35271698 Get It

Abstract Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The existing paradigms in the management of LCH in adults are mostly derived from the pediatric literature. Over the last decade, the discovery of clonality and MAPK-ERK pathway mutations in most cases led to the recognition of LCH as a hematopoietic neoplasm, opening the doors for treatment with targeted therapies. These advances have necessitated an update of the existing recommendations for the diagnosis and treatment of LCH in adults. This document presents consensus recommendations that resulted from the discussions at the annual Histiocyte Society meeting in 2019, encompassing clinical features, classification, diagnostic criteria, treatment algorithm, and response assessment for adults with LCH. The recommendations favor the use of 18F-Fluorodeoxyglucose positron emission tomography-based imaging for staging and response assessment in the majority of cases. Most adults with unifocal disease may be cured by local therapies, while the first-line treatment for single-system pulmonary LCH remains smoking cessation. Among patients not amenable or unresponsive to these treatments and/or have multifocal and multisystem disease, systemic treatments are recommended. Preferred systemic treatments in adults with LCH include cladribine or cytarabine, with the emerging role of targeted (BRAF and MEK inhibitor) therapies. Despite documented responses to treatments, many patients struggle with a high symptom burden from pain, fatigue, and mood disorders that should be acknowledged and managed appropriately.
Mast cell sarcoma: 2 Mayo Clinic cases
Singh, Amritpal , Pardanani, Animesh , He, Rong , Tefferi, Ayalew , Reichard, Kaaren K. , Pardanani, Animesh , He, Rong , Tefferi, Ayalew , Alkhateeb, Hassan B. , Orazi, Attilio

Mayo Clinic

American Journal of Hematology | March 10, 2022 | Volume: 97 | Issue: 10 | Pages: 1381-1383

10.1002/ajh.26525 | PMID 35266568 Get It